Healthcare >> CEO Interviews >> March 2, 1998

Richard L. Love – Ilex Oncology (ilxo)

RICHARD L. LOVE has served as President, Chief Executive Officer and a Director of ILEX Oncology, Inc. since it began operations in 1994. He has more than 34 years of industry experience, with more than 20 years in the biosciences industry. Prior to forming ILEX, Mr. Love was Chief Operating Officer of CTRC Research from 1991 to 1994. From 1983 through 1991, he served as CEO of Triton Biosciences, Inc., a subsidiary of Shell Oil Company, and led the sale of Triton Biosciences Inc. to Berlex Laboratories, Inc., a subsidiary of Schering, AG Triton developed two drugs that were ultimately approved by the FDA ' Fludara (fludarabine phosphate) and Betaseron (recombinant human beta interferon). Mr. Love earned his BS and MS in Chemical Engineering from Virginia Polytechnic Institute. Profile
TWST: Give us a background summary, a brief historical sketch of ILEX

Oncology, and then bring us up to date. What is the company doing today?

Mr. Love: ILEX is a drug development company